-
These Analysts Love Tesla's Potential, But Balk At Its Valuation
Thursday, August 16, 2018 - 2:20pm | 474Read More...Tesla Inc (NASDAQ: TSLA) has been the talk of the town on Wall Street in recent weeks, and analysts are weighing in on Tesla and CEO Elon Musk’s controversial proposal to take the company private on a seemingly daily basis. Impressive Production Evercore ISI analyst George Galliers visited...
-
What Wall Street Is Saying About Musk Taking Tesla Private
Wednesday, August 8, 2018 - 12:05pm | 1967Read More...Tuesday afternoon, Tesla Inc (NASDAQ: TSLA) CEO Elon Musk casually tweeted his intent to explore a go-private path for the controversial automaker. After a mid-session halt, Tesla’s stock closed up 10.3 percent. Here’s what analysts had to say about the startling, unclear message. It...
-
Analyst: Marvell Technology Is An Attractive AI, Big Data And Storage Play
Wednesday, June 27, 2018 - 4:21pm | 380Read More...Marvell Techology Group Ltd. (NASDAQ: MRVL) shares are attractive at today's levels and poised to benefit from growth trends in the data sector, according to Evercore ISI. The Analyst Evercore ISI analyst C.J. Muse initiated coverage of Marvell with an Outperform rating and $27 price...
-
Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives
Saturday, June 23, 2018 - 10:21am | 524Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) — a clinical-stage biopharmaceutical company focused on bringing to market advanced products based on the potential of gene therapy — have been highly volatile, but the company has a "clear path" toward commercialization,...
-
Evercore Sees New Value In GM Cruise, Upgrades On SoftBank Investment
Thursday, May 31, 2018 - 10:57am | 309Read More...General Motors Company (NYSE: GM) was off to a good start Thursday, with a strong SoftBank investment bolstering the firm’s prospects in autonomous vehicles. A sell-side upgrade extended the stock’s rally. The Rating Evercore ISI analyst George Galliers upgraded GM from In Line...
-
Evercore ISI Raises 2019 Estimates For Lodging Stocks, Says Environment Favorable For Sector
Sunday, May 20, 2018 - 5:17pm | 569Read More...Evercore ISI is refining its estimates on lodging companies in the wake of first-quarter earnings reports and raised its 2019 EPS estimates across the board. The Analyst Evercore ISI’s Rich Hightower. The Ratings DiamondRock Hospitality Company (NYSE: DRH) was downgraded from...
-
A Spotify Sell-Side Roundup: Wall Street Largely Bullish On Streaming Platform's Stock
Wednesday, May 2, 2018 - 1:14pm | 753Read More...The quiet period for streaming music provider Spotify Technology SA (NYSE: SPOT) expired Monday, which means all research firms are permitted to publish reports on the stock. Here's what the Street is saying. The Analysts Evercore ISI's Anthony DiClemente initiated...
-
Listen To The Music: Evercore Names 5 Reasons Why Spotify Is A Winner
Monday, April 30, 2018 - 11:55am | 440Read More...Streaming music provider Spotify Technology SA (NYSE: SPOT) is the market leader, with "significant" growth potential, according to Evercore ISI. The Analyst Evercore's Anthony DiClemente initiated coverage of Spotify's stock with an Outperform and $190 price target. The...
-
Hologic's SculpSure Body Contouring Treatment Scores Distribution Win
Tuesday, April 17, 2018 - 3:26pm | 409Read More...The hair and skin cosmetic procedure provider LightRx Face & Body announced a partnership Tuesday in which it will provide Hologic, Inc. (NASDAQ: HOLX)'s SculpSure non-invasive laser body contouring treatment at its 80 nationwide locations. The Analyst Evercore ISI analyst Vijay...
-
Evercore: Nvidia Can 'Power Through' Bitmain Ethereum Mining Tailwinds
Wednesday, April 4, 2018 - 1:13pm | 377Read More...NVDIA Corporation (NASDAQ: NVDA) fell about 2 percent Wednesday after Bitmain announced its highly anticipated application-specific integrated circuit (ASIC) for cryptocurrency mining. The company said the new ASIC will be available in July. This could be bad news for Nvidia and its GPU sales, but...
-
Kirby Shares Attractive As Inflection Point Nears, Says Evercore
Friday, February 2, 2018 - 2:40pm | 374Read More...Tank barge operator Kirby Corporation (NYSE: KEX) announced fourth quarter results, showing better than adjusted earnings per share and revenue growth of about 63 percent. The Analyst Evercore ISI analyst Jonathan Chappell upgraded shares of Kirby from In Line to Attractive, and increased his...
-
Analyst: United Continental Has Hit Peak Altitude
Wednesday, January 24, 2018 - 10:59am | 417Read More...United Continental Holdings Inc (NYSE: UAL) reported fourth-quarter results Tuesday and provided an update to its outlook that prompted at least one Wall Street analyst to drop their bullish stance. The Analyst Evercore ISI's Duane Pfennigwerth downgraded United Continental...
-
Analyst: It Will Be 'Difficult' For Twitter To Replace Anthony Noto
Monday, January 22, 2018 - 1:31pm | 422Read More...Twitter's Chief Operating Officer Anthony Noto, perhaps the most visible Twitter Inc (NYSE: TWTR) executive aside from CEO Jack Dorsey, could leave the social media to accept the CEO job at Social Finance Inc., according to a recent report from The Wall Street Journal. That's not great...
-
Palo Alto Networks Has 'Compelling' Risk-Reward, Says Evercore ISI
Thursday, January 18, 2018 - 10:54am | 408Read More...Security vendor Palo Alto Networks Inc (NYSE: PANW) has room to flourish in multiple arenas, according to Evercore ISI. The Analyst Evercore ISI analyst Ken Talanian upgraded shares of Palo Alto Networks from In Line to Outperform and increased the price target from $150 to $180. The Thesis...
-
Wall Street Reacts To Spark Therapeutics' $850K Genetic Blindness Treatment
Wednesday, January 3, 2018 - 12:59pm | 589Read More...The first gene therapy treatment ever approved in the U.S. comes with a steep price tag. On Wednesday, Spark Therapeutics Inc (NASDAQ: ONCE) announced it will charge $425,000 per eye for one-time treatments of a rare genetic retinal disease that causes blindness. The new therapy could be a huge...















